CLINICAL BENEFIT OF LUSPATERCEPT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) AND HIGH TRANSFUSION BURDEN (HTB) IN THE PHASE 3 MEDALIST STUDY
Author(s): ,
Amer M. Zeidan
Affiliations:
Department of Internal Medicine,Yale School of Medicine and Yale Cancer Center, Yale University,New Haven, CT,United States
,
Guillermo Garcia-Manero
Affiliations:
Department of Leukemia,University of Texas MD Anderson Cancer Center,Houston, TX,United States
,
Amy E. DeZern
Affiliations:
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Baltimore, MD,United States
,
Pierre Fenaux
Affiliations:
Service d'Hématologie Séniors,Hôpital Saint-Louis, Université Paris 7,Paris,France
,
Peter L. Greenberg
Affiliations:
Stanford University Cancer Center,Stanford, CA,United States
,
Michael R. Savona
Affiliations:
Vanderbilt-Ingram Cancer Center,Vanderbilt University School of Medicine,Nashville, TN,United States
,
Joseph G. Jurcic
Affiliations:
Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center,Columbia University Medical Center,New York, NY,United States
,
Amit Verma
Affiliations:
Department of Oncology,Albert Einstein College of Medicine, Montefiore Medical Center,Bronx, NY,United States
,
Ghulam J. Mufti
Affiliations:
Department of Haemato-Oncology,King's College London,London,United Kingdom
,
Rena Buckstein
Affiliations:
Odette Cancer Centre,Sunnybrook Health Sciences Centre,Toronto, ON,Canada
,
Valeria Santini
Affiliations:
MDS Unit,Azienda Ospedaliero Universitaria (AOU) Careggi, University of Florence,Florence,Italy
,
Abderrahmane Laadem
Affiliations:
Bristol-Myers Squibb,Summit, NJ,United States
,
Jennie Zhang
Affiliations:
Bristol-Myers Squibb,Summit, NJ,United States
,
Anita Rampersad
Affiliations:
Bristol-Myers Squibb,Summit, NJ,United States
,
Daniel Sinsimer
Affiliations:
Bristol-Myers Squibb,Summit, NJ,United States
,
Chrystal Louis
Affiliations:
Bristol-Myers Squibb,Summit, NJ,United States
,
Peter G. Linde
Affiliations:
Acceleron Pharma,Cambridge, MA,United States
,
Uwe Platzbecker
Affiliations:
Medical Clinic and Policlinic 1, Hematology and Cellular Therapy,University Hospital Leipzig,Leipzig,Germany
Mikkael A. Sekeres
Affiliations:
Department of Hematology and Medical Oncology,Cleveland Clinic,Cleveland, OH,United States
EHA Library. Zeidan A. 06/12/20; 294715; EP798
Amer Zeidan
Amer Zeidan
Contributions
Abstract

Abstract: EP798

Type: e-Poster

Presentation during EHA25: All e-Poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Background
Anemic patients with LR-MDS and baseline HTB have very few treatment options and constitute a patient population with significant clinical unmet need. MEDALIST is an ongoing randomized, placebo-controlled, phase 3 study evaluating the efficacy and safety of luspatercept, a first-in-class erythroid maturation agent, for treatment of anemia in patients with LR-MDS (Fenaux P & Platzbecker U, et al. N Engl J Med. 2020;382:140-51; NCT02631070).

Aims
In this secondary analysis of the MEDALIST trial, we sought to evaluate the clinical benefit of luspatercept in patients with LR-MDS and HTB.

Methods
Eligible patients were aged ≥18 years; had Revised International Prognostic Scoring System-defined Very low-, Low-, or Intermediate-risk MDS with ring sideroblasts (RS); were refractory, intolerant, or unlikely to respond to erythropoiesis-stimulating agents (serum erythropoietin >200 U/L); and had anemia requiring regular red blood cell (RBC) transfusions (≥2 units/8 weeks in the 16 weeks prior to randomization). All patients provided informed written consent. 229 patients were randomized 2:1 to luspatercept (starting dose 1.0 mg/kg; titration up to 1.75 mg/kg allowed) or placebo subcutaneously every 3 weeks. HTB was defined as ≥6 RBC units transfused/8 weeks.

Results
153 patients were randomized to luspatercept and 76 to placebo; 66 and 33 of them respectively had HTB at baseline. As of July 1, 2019, 23/66 (34.8%) and 12/66 (18.2%) HTB patients receiving luspatercept achieved a ≥50% and ≥75% reduction from baseline in RBC transfusion burden over ≥24 weeks, respectively, vs 3/33 (9.1%; P=0.0063) and 1/33 (3.0%; P=0.0363) patients receiving placebo. 6/66 (9.1%) luspatercept-treated HTB patients and 1/33 (3.0%) placebo-treated HTB patient achieved RBC‑transfusion independence (TI) ≥8 weeks in Weeks 1–24 (P=0.2699). The median (range) time to achieve RBC-TI with luspatercept was 50.0 days (1.0–100.0) and median (range) duration of RBC-TI in the luspatercept arm was 42.6 weeks (8.4–81.1). Mean number of transfusion events in Weeks 1–24 was 9.2 in the luspatercept arm vs 12.4 in the placebo arm (hazard ratio 0.794; 95% confidence interval 0.660–0.956).

65/66 (98.5%) luspatercept- and 29/33 (87.9%) placebo-treated HTB patients reported ≥1 treatment-emergent adverse event (TEAE); 11/66 (16.7%) and 3/33 (9.1%) patients, respectively, reported ≥1 TEAE leading to discontinuation. 28/66 (42.4%) luspatercept- and 15/33 (45.5%) placebo-treated HTB patients reported ≥1 serious TEAE. Incidence of grade 3–4 TEAEs in HTB patients was similar between arms (53.0% luspatercept vs 54.5% placebo).

Conclusion
Luspatercept treatment resulted in clinically significant reductions in transfusion burden and reduced number of transfusion events in HTB patients with LR-MDS with RS. Luspatercept was well tolerated in HTB patients, consistent with the overall study population.

Session topic: 10. Myelodysplastic syndromes - Clinical

Keyword(s): Clinical trial, MDS, Phase III

Abstract: EP798

Type: e-Poster

Presentation during EHA25: All e-Poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Background
Anemic patients with LR-MDS and baseline HTB have very few treatment options and constitute a patient population with significant clinical unmet need. MEDALIST is an ongoing randomized, placebo-controlled, phase 3 study evaluating the efficacy and safety of luspatercept, a first-in-class erythroid maturation agent, for treatment of anemia in patients with LR-MDS (Fenaux P & Platzbecker U, et al. N Engl J Med. 2020;382:140-51; NCT02631070).

Aims
In this secondary analysis of the MEDALIST trial, we sought to evaluate the clinical benefit of luspatercept in patients with LR-MDS and HTB.

Methods
Eligible patients were aged ≥18 years; had Revised International Prognostic Scoring System-defined Very low-, Low-, or Intermediate-risk MDS with ring sideroblasts (RS); were refractory, intolerant, or unlikely to respond to erythropoiesis-stimulating agents (serum erythropoietin >200 U/L); and had anemia requiring regular red blood cell (RBC) transfusions (≥2 units/8 weeks in the 16 weeks prior to randomization). All patients provided informed written consent. 229 patients were randomized 2:1 to luspatercept (starting dose 1.0 mg/kg; titration up to 1.75 mg/kg allowed) or placebo subcutaneously every 3 weeks. HTB was defined as ≥6 RBC units transfused/8 weeks.

Results
153 patients were randomized to luspatercept and 76 to placebo; 66 and 33 of them respectively had HTB at baseline. As of July 1, 2019, 23/66 (34.8%) and 12/66 (18.2%) HTB patients receiving luspatercept achieved a ≥50% and ≥75% reduction from baseline in RBC transfusion burden over ≥24 weeks, respectively, vs 3/33 (9.1%; P=0.0063) and 1/33 (3.0%; P=0.0363) patients receiving placebo. 6/66 (9.1%) luspatercept-treated HTB patients and 1/33 (3.0%) placebo-treated HTB patient achieved RBC‑transfusion independence (TI) ≥8 weeks in Weeks 1–24 (P=0.2699). The median (range) time to achieve RBC-TI with luspatercept was 50.0 days (1.0–100.0) and median (range) duration of RBC-TI in the luspatercept arm was 42.6 weeks (8.4–81.1). Mean number of transfusion events in Weeks 1–24 was 9.2 in the luspatercept arm vs 12.4 in the placebo arm (hazard ratio 0.794; 95% confidence interval 0.660–0.956).

65/66 (98.5%) luspatercept- and 29/33 (87.9%) placebo-treated HTB patients reported ≥1 treatment-emergent adverse event (TEAE); 11/66 (16.7%) and 3/33 (9.1%) patients, respectively, reported ≥1 TEAE leading to discontinuation. 28/66 (42.4%) luspatercept- and 15/33 (45.5%) placebo-treated HTB patients reported ≥1 serious TEAE. Incidence of grade 3–4 TEAEs in HTB patients was similar between arms (53.0% luspatercept vs 54.5% placebo).

Conclusion
Luspatercept treatment resulted in clinically significant reductions in transfusion burden and reduced number of transfusion events in HTB patients with LR-MDS with RS. Luspatercept was well tolerated in HTB patients, consistent with the overall study population.

Session topic: 10. Myelodysplastic syndromes - Clinical

Keyword(s): Clinical trial, MDS, Phase III

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies